210: How you approach precision medicine mattersfor some patients more than others

Published: May 28, 2024, 5:15 a.m.

It's no secret that healthcare is becoming more and more personalized \u2013 or \u201cbespoke\u201d \u2013 as increasingly sophisticated diagnostics and therapeutics continue to explode into the market. This vast pipeline is redefining the industry in several ways\u2014but there is real risk associated if the stakeholders responsible for developing, delivering, and paying for these innovations aren\u2019t baking health equity into their business models.

\n\n

Last week, in the first episode of our run up to the Advisory Board Clinical Innovation Summit: Revolutions in Specialty Care, we discussed Advisory Board\u2019s prediction for the future of oncology. This week, host Rachel (Rae) Woods invites Advisory Board experts Amanda Okaka and Fanta Cherif to break down the health equity conundrum presented by precision medicine: Will precision medicine reduce health disparities, or exacerbate them? The answer depends on the actions\u2014big and small\u2014of industry leaders.

\n\n

Links:

\n\n\n\n


\n\n

Register for the Clinical Innovation Summit

\n\n


\n\n

A transcript of this episode as well as more information and resources can be found on radioadvisory.advisory.com.